ProCE Banner Activity

Latest Therapeutic Advancements in Targeting TROP-2 in NSCLC


Download this slideset from a live symposium at ELCC 2024 for an expert overview of the latest clinical data for TROP-2 ADCs in advanced NSCLC, including monotherapy vs standard-of-care docetaxel in the second-line setting, considerations for biomarker assessment, and future directions with combination regimens and novel TROP-2 ADCs.

Released: March 19, 2024



Luis Paz-Ares

Luis Paz-Ares, MD, PhD

Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Madrid, Spain

Helena Yu

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.